Cargando…

Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study

BACKGROUND: Postoperative abdominal adhesions (PAAs) are present in more than 90% of patients undergoing abdominal surgery. They are a cause of chronic pain, hospitalizations, multiple surgeries, and infertility in women of reproductive age. The participation of three processes have been recognized:...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzmán-Valdivia Gómez, Gilberto, Tena-Betancourt, Eduardo, Angulo Trejo, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666521/
https://www.ncbi.nlm.nih.gov/pubmed/34917351
http://dx.doi.org/10.1016/j.amsu.2021.103132
_version_ 1784614224443473920
author Guzmán-Valdivia Gómez, Gilberto
Tena-Betancourt, Eduardo
Angulo Trejo, Mónica
author_facet Guzmán-Valdivia Gómez, Gilberto
Tena-Betancourt, Eduardo
Angulo Trejo, Mónica
author_sort Guzmán-Valdivia Gómez, Gilberto
collection PubMed
description BACKGROUND: Postoperative abdominal adhesions (PAAs) are present in more than 90% of patients undergoing abdominal surgery. They are a cause of chronic pain, hospitalizations, multiple surgeries, and infertility in women of reproductive age. The participation of three processes have been recognized: coagulation, fibrinolysis, and inflammation. The usefulness of subcutaneous enoxaparin in their prevention has been established. The objective is to establish the safest and most efficient dose for PAA prevention by testing five different doses of subcutaneous enoxaparin (0.25, 0.5, 1, 1.5, and 2 mg/kg/day) given in one dose/day for seven days. MATERIAL AND METHODS: Fifty Sprague-Dawley rats were studied, 10 in each group. Adhesions were induced through controlled rubbing of the cecum and suturing of an incision in the terminal ileum. Two independent observers recorded the degree of adhesion formation at 14 days and histologically studied the adhesions. STATISTICAL ANALYSIS: ANOVA compared group averages. The nonparametric Kruskal-Wallis test was used to identify group differences. RESULTS: The 0.5 mg/kg/day group had greater formation of adhesions (p < 0.001). There was no significant difference between the 1.5 and 2 mg/kg/day groups, though the latter group had an incidence of 27.2% of bleeding in the abdominal cavity. The degree of adhesions in the histological sections coincided with the macroscopic findings. The interobserver agreement was kappa = 0.88 (very good). CONCLUSION: The safe and effective dose of subcutaneous enoxaparin to prevent PAA formation was 0.5–1.5 mg/kg/day for seven days.
format Online
Article
Text
id pubmed-8666521
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86665212021-12-15 Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study Guzmán-Valdivia Gómez, Gilberto Tena-Betancourt, Eduardo Angulo Trejo, Mónica Ann Med Surg (Lond) Cohort Study BACKGROUND: Postoperative abdominal adhesions (PAAs) are present in more than 90% of patients undergoing abdominal surgery. They are a cause of chronic pain, hospitalizations, multiple surgeries, and infertility in women of reproductive age. The participation of three processes have been recognized: coagulation, fibrinolysis, and inflammation. The usefulness of subcutaneous enoxaparin in their prevention has been established. The objective is to establish the safest and most efficient dose for PAA prevention by testing five different doses of subcutaneous enoxaparin (0.25, 0.5, 1, 1.5, and 2 mg/kg/day) given in one dose/day for seven days. MATERIAL AND METHODS: Fifty Sprague-Dawley rats were studied, 10 in each group. Adhesions were induced through controlled rubbing of the cecum and suturing of an incision in the terminal ileum. Two independent observers recorded the degree of adhesion formation at 14 days and histologically studied the adhesions. STATISTICAL ANALYSIS: ANOVA compared group averages. The nonparametric Kruskal-Wallis test was used to identify group differences. RESULTS: The 0.5 mg/kg/day group had greater formation of adhesions (p < 0.001). There was no significant difference between the 1.5 and 2 mg/kg/day groups, though the latter group had an incidence of 27.2% of bleeding in the abdominal cavity. The degree of adhesions in the histological sections coincided with the macroscopic findings. The interobserver agreement was kappa = 0.88 (very good). CONCLUSION: The safe and effective dose of subcutaneous enoxaparin to prevent PAA formation was 0.5–1.5 mg/kg/day for seven days. Elsevier 2021-12-03 /pmc/articles/PMC8666521/ /pubmed/34917351 http://dx.doi.org/10.1016/j.amsu.2021.103132 Text en © 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Cohort Study
Guzmán-Valdivia Gómez, Gilberto
Tena-Betancourt, Eduardo
Angulo Trejo, Mónica
Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study
title Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study
title_full Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study
title_fullStr Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study
title_full_unstemmed Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study
title_short Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study
title_sort different doses of enoxaparin in the prevention of postoperative abdominal adhesions. experimental study
topic Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666521/
https://www.ncbi.nlm.nih.gov/pubmed/34917351
http://dx.doi.org/10.1016/j.amsu.2021.103132
work_keys_str_mv AT guzmanvaldiviagomezgilberto differentdosesofenoxaparininthepreventionofpostoperativeabdominaladhesionsexperimentalstudy
AT tenabetancourteduardo differentdosesofenoxaparininthepreventionofpostoperativeabdominaladhesionsexperimentalstudy
AT angulotrejomonica differentdosesofenoxaparininthepreventionofpostoperativeabdominaladhesionsexperimentalstudy